MXPA03004114A - Derivados de cianopirrolidina. - Google Patents

Derivados de cianopirrolidina.

Info

Publication number
MXPA03004114A
MXPA03004114A MXPA03004114A MXPA03004114A MXPA03004114A MX PA03004114 A MXPA03004114 A MX PA03004114A MX PA03004114 A MXPA03004114 A MX PA03004114A MX PA03004114 A MXPA03004114 A MX PA03004114A MX PA03004114 A MXPA03004114 A MX PA03004114A
Authority
MX
Mexico
Prior art keywords
cyanopyrrolidine derivatives
cyanopyrrolidine
derivatives
Prior art date
Application number
MXPA03004114A
Other languages
English (en)
Inventor
Kazuya Kameo
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of MXPA03004114A publication Critical patent/MXPA03004114A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MXPA03004114A 2000-11-10 2001-11-09 Derivados de cianopirrolidina. MXPA03004114A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000344036 2000-11-10
JP2001215766 2001-07-16
PCT/JP2001/009818 WO2002038541A1 (fr) 2000-11-10 2001-11-09 Derives de cyanopyrrolidine

Publications (1)

Publication Number Publication Date
MXPA03004114A true MXPA03004114A (es) 2003-08-19

Family

ID=26603777

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03004114A MXPA03004114A (es) 2000-11-10 2001-11-09 Derivados de cianopirrolidina.

Country Status (23)

Country Link
US (3) US20040072892A1 (es)
EP (2) EP1333025A4 (es)
JP (1) JP3987890B2 (es)
KR (3) KR100680079B1 (es)
CN (1) CN1298703C (es)
AU (2) AU1274502A (es)
BG (1) BG107799A (es)
BR (1) BR0114851A (es)
CA (1) CA2428271C (es)
CZ (1) CZ20031250A3 (es)
EA (2) EA006204B1 (es)
EE (1) EE200300175A (es)
HK (1) HK1061688A1 (es)
HR (2) HRP20030366A2 (es)
HU (1) HUP0302248A2 (es)
IL (2) IL155776A0 (es)
MX (1) MXPA03004114A (es)
NO (2) NO20031949L (es)
NZ (1) NZ525705A (es)
PL (1) PL361463A1 (es)
SK (1) SK5632003A3 (es)
TW (1) TWI243162B (es)
WO (1) WO2002038541A1 (es)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002306823B2 (en) 2001-03-27 2006-05-11 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2003002530A2 (en) 2001-06-27 2003-01-09 Smithkline Beecham Corporation Pyrrolidines as dipeptidyl peptidase inhibitors
CN1990468A (zh) * 2001-06-27 2007-07-04 史密丝克莱恩比彻姆公司 作为二肽酶抑制剂的氟代吡咯烷
DE60221983T2 (de) 2001-06-27 2008-05-15 Smithkline Beecham Corp. Fluorpyrrolidine als dipeptidyl-peptidase inhibitoren
GB0125445D0 (en) * 2001-10-23 2001-12-12 Ferring Bv Protease Inhibitors
AU2002360732A1 (en) * 2001-12-26 2003-07-24 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
EP1338595B1 (en) 2002-02-25 2006-05-03 Eisai Co., Ltd. Xanthine derivatives as DPP-IV inhibitors
HUP0200849A2 (hu) * 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
WO2003095425A1 (fr) * 2002-05-09 2003-11-20 Taisho Pharmaceutical Co.,Ltd. Derives de cyanopyrrolidine
MXPA04011958A (es) * 2002-06-04 2005-03-31 Pfizer Prod Inc Amidas ciclicas fluoradas como inhibidores de la dipeptidil peptidasa iv.
WO2004007446A1 (ja) * 2002-07-10 2004-01-22 Yamanouchi Pharmaceutical Co., Ltd. 新規なアゼチジン誘導体又はその塩
TW200401635A (en) * 2002-07-23 2004-02-01 Yamanouchi Pharma Co Ltd 2-Cyano-4-fluoropyrrolidine derivative or salt thereof
BR0313831A (pt) * 2002-08-29 2005-07-05 Taisho Pharmaceutical Co Ltd Sais benzenossulfonato de derivados de 4-flúor-2-cianopirrolidina
BR0316327A (pt) * 2002-11-18 2005-09-27 Pfizer Prod Inc Amidas cìclicas fluorinadas inibidoras de dipeptidilpeptidase iv
JP2005170792A (ja) * 2002-11-22 2005-06-30 Mitsubishi Pharma Corp Ｌ−プロリン誘導体およびその医薬としての用途。
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308352A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
KR20050122220A (ko) * 2003-03-25 2005-12-28 다케다 샌디에고, 인코포레이티드 디펩티딜 펩티다제 억제제
EP1622870A2 (en) * 2003-05-05 2006-02-08 Prosidion Ltd. Glutaminyl based dp iv-inhibitors
DE602004026289D1 (de) 2003-05-05 2010-05-12 Probiodrug Ag Glutaminylcyclase-hemmer
NZ543146A (en) 2003-05-05 2008-09-26 Probiodrug Ag Use of effectors of glutaminyl cyclase (QC) activity in combination with inhibitors of DP IV or DP IV-like enzymes for the treatment of conditions that can be treated by modulation of QC-and/or DPIV-activity
DE202004021723U1 (de) 2003-05-05 2010-07-15 Probiodrug Ag Medizinische Verwendung von Hemmern von Glutaminyl- und Glutamatcyclasen
WO2004103993A1 (en) * 2003-05-14 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
AU2004238719A1 (en) * 2003-05-15 2004-11-25 Taisho Pharmaceutical Co., Ltd. Cyanofluoropyrrolidine derivative
RU2006107553A (ru) * 2003-08-13 2007-09-20 Такеда Фармасьютикал Компани Лимитед (Jp) Производные 4-пиримидона и их применение в качестве ингибиторов пептидилпептидаз
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20050065144A1 (en) * 2003-09-08 2005-03-24 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US7790734B2 (en) * 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
BRPI0415409A (pt) 2003-10-15 2006-12-05 Probiodrug Ag uso de efetuadores de ciclases de glutaminila e glutamato
NZ546887A (en) 2003-11-03 2009-04-30 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
KR20130105741A (ko) 2003-11-17 2013-09-25 노파르티스 아게 디펩티딜 펩티다제 ⅳ 억제제의 용도
PL3738585T3 (pl) 2004-01-20 2023-04-17 Novartis Ag Preparat i sposób jego bezpośredniego prasowania
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
WO2005073186A1 (ja) * 2004-01-29 2005-08-11 Ono Pharmaceutical Co., Ltd. ピロリジン誘導体
US7230002B2 (en) * 2004-02-03 2007-06-12 Glenmark Pharmaceuticals Ltd. Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof
JP4996926B2 (ja) 2004-02-05 2012-08-08 プロビオドルグ エージー グルタミニルシクラーゼの新規の阻害剤
NZ548440A (en) * 2004-02-05 2009-07-31 Kyorin Seiyaku Kk Bicycloester derivative inhibitng DPP-IV for treatment of diabetes or similar
JPWO2005077900A1 (ja) * 2004-02-18 2007-10-18 杏林製薬株式会社 ビシクロアミド誘導体
CA2557275C (en) * 2004-02-27 2012-06-05 Kyorin Pharmaceutical Co., Ltd. Bicyclo derivative
WO2005087235A1 (en) 2004-03-09 2005-09-22 National Health Research Institutes Pyrrolidine compounds
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EA013427B1 (ru) * 2004-03-15 2010-04-30 Такеда Фармасьютикал Компани Лимитед Ингибиторы дипептидилпептидазы
EP1586573B1 (en) 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, processes for their preparation and their use as pharmaceuticals
TW200604167A (en) * 2004-04-27 2006-02-01 Astellas Pharma Inc Pyrrolidine derivatives
AU2005247684B2 (en) 2004-05-12 2008-10-23 Pfizer Products Inc. Proline derivatives and their use as dipeptidyl peptidase IV inhibitors
WO2005118555A1 (en) * 2004-06-04 2005-12-15 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
AU2005267093B2 (en) 2004-07-23 2009-10-01 Nuada Llc Peptidase inhibitors
KR20070073887A (ko) 2004-10-12 2007-07-10 그렌마크 파머수티칼스 에스. 아. 신규한 디펩티딜 펩티다제 ⅳ 억제제, 이를 함유하는약제학적 조성물, 및 이의 제조공정
JP2008019168A (ja) * 2004-10-22 2008-01-31 Astellas Pharma Inc ２−シアノ−４−フルオロピロリジン誘導体の製造法
JP2008524331A (ja) * 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
JP2008024592A (ja) * 2005-01-28 2008-02-07 Taisho Pharmaceut Co Ltd シアノピロリジン誘導体含有固形製剤用組成物、それを含有する固形製剤及びその製造方法
WO2006090244A1 (en) * 2005-02-22 2006-08-31 Glenmark Pharmaceuticals S.A. New adamantane derivatives as dipeptidyl, peptidase iv inhibitors, processes for their preparation, and pharmaceutical compositions containing them
MX2007011453A (es) 2005-04-22 2008-02-12 Alantos Pharmaceuticals Holding Inc Inhibidores de la dipeptidil peptidasa-iv.
JP2008115080A (ja) * 2005-04-22 2008-05-22 Taisho Pharmaceutical Co Ltd 併用医薬
CA2610022A1 (en) 2005-06-06 2006-12-14 Georgetown University Compositions and methods for lipo modeling
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
MY152185A (en) 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
KR101352588B1 (ko) * 2005-09-14 2014-01-17 다케다 야쿠힌 고교 가부시키가이샤 당뇨병 치료용 디펩티딜 펩티다아제 억제제
ME02005B (me) 2005-09-14 2012-08-31 Takeda Pharmaceuticals Co Inhibitori dipeptidil peptidaze za lečenje dijabetesa
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
CN101360723A (zh) * 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
KR20080077024A (ko) 2005-12-19 2008-08-20 트러스티즈 오브 터프츠 칼리지 소프트 단백질분해효소 억제자 및 이의 프로-소프트 폼
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
CN101395131B (zh) * 2006-03-08 2012-11-14 杏林制药株式会社 氨基乙酰基吡咯烷甲腈衍生物的制备方法及其制备中间体
JP2009531456A (ja) * 2006-03-28 2009-09-03 武田薬品工業株式会社 （ｒ）−３−アミノピペリジン二塩酸塩の調製
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
MX2008012756A (es) * 2006-04-03 2009-03-05 Matrix Lab Ltd Inhibidores de dipeptidil peptidasa iv novedosos y procesos para su preparacion y composiciones farmaceuticas que los contienen.
MEP27308A (en) 2006-04-11 2010-06-10 Arena Pharm Inc Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
EP2007734A1 (en) 2006-04-12 2008-12-31 Probiodrug AG Enzyme inhibitors
JP5152519B2 (ja) 2006-06-29 2013-02-27 大正製薬株式会社 Ｃ−フェニル１−チオグルシト−ル化合物
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
JP5523107B2 (ja) 2006-11-30 2014-06-18 プロビオドルグ エージー グルタミニルシクラーゼの新規阻害剤
JPWO2008072726A1 (ja) 2006-12-14 2010-04-02 大正製薬株式会社 １−フェニル １−チオ−ｄ−グルシト−ル誘導体
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
WO2008114857A1 (ja) 2007-03-22 2008-09-25 Kyorin Pharmaceutical Co., Ltd. アミノアセチルピロリジンカルボニトリル誘導体の製造方法
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
WO2009037719A1 (en) * 2007-09-21 2009-03-26 Lupin Limited Novel compounds as dipeptidyl peptidase iv (dpp iv) inhibitors
KR101634656B1 (ko) 2008-03-05 2016-06-29 내셔날 헬스 리서치 인스티튜트 피롤리딘 유도체
EP2146210A1 (en) * 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
WO2010016584A1 (ja) * 2008-08-07 2010-02-11 杏林製薬株式会社 ビシクロ[２．２．２]オクチルアミン誘導体の製造方法
JPWO2010018866A1 (ja) * 2008-08-14 2012-01-26 杏林製薬株式会社 安定化された医薬組成物
CA2737738A1 (en) * 2008-09-18 2010-03-25 Astellas Pharma Inc. Heterocyclic carboxamide compounds
AU2010204144B2 (en) 2009-01-09 2012-02-16 Orchid Research Laboratories Ltd. Dipeptidyl peptidase IV inhibitors
GB2483614B (en) 2009-06-18 2014-12-03 Lupin Ltd 2-Amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent dpp-iv inhibitors
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
EA022007B1 (ru) 2009-09-11 2015-10-30 Пробиодруг Аг Гетероциклические производные в качестве ингибиторов глутаминилциклазы
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
BR112012022478B1 (pt) 2010-03-10 2021-09-21 Probiodrug Ag Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica
JP2013523819A (ja) 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2619198A1 (en) 2010-09-22 2013-07-31 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
TWI500613B (zh) 2012-10-17 2015-09-21 Cadila Healthcare Ltd 新穎之雜環化合物
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
CN103922986B (zh) * 2013-01-16 2017-02-15 上海彩迩文生化科技有限公司 维大列汀及其类似物、中间体及其制备方法和应用
EP3267994A4 (en) 2015-03-09 2018-10-31 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
WO2018162722A1 (en) 2017-03-09 2018-09-13 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Dpp-4 inhibitors for use in treating bone fractures
WO2018187350A1 (en) 2017-04-03 2018-10-11 Coherus Biosciences Inc. PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
WO2021165927A1 (en) * 2020-02-21 2021-08-26 Wockhardt Bio Ag 2-cyanopyrroldines, -piperidines or -dazepines as hyperglycemic agents

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU189214B (en) * 1983-01-20 1986-06-30 Alkaloida Vegyeszeti Gyar,Hu Process for preparing pyrroline and pyrrolidine carboxamide derivatives
SU1705283A1 (ru) * 1989-01-30 1992-01-15 Чувашский государственный университет им.И.Н.Ульянова Способ получени 3-замещенных 1-N-диалкиламино-2,2-(дициано)метилен-4-цианопирролидинов
IL111785A0 (en) * 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW492957B (en) * 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6107317A (en) * 1999-06-24 2000-08-22 Novartis Ag N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6110949A (en) * 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6172081B1 (en) * 1999-06-24 2001-01-09 Novartis Ag Tetrahydroisoquinoline 3-carboxamide derivatives
CA2390231A1 (en) * 1999-11-12 2001-05-17 Paul Jackson Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
AU2002306823B2 (en) * 2001-03-27 2006-05-11 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CA2450579A1 (en) * 2001-06-20 2003-01-03 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
GB0115517D0 (en) * 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
DE60221983T2 (de) * 2001-06-27 2008-05-15 Smithkline Beecham Corp. Fluorpyrrolidine als dipeptidyl-peptidase inhibitoren
CN1990468A (zh) * 2001-06-27 2007-07-04 史密丝克莱恩比彻姆公司 作为二肽酶抑制剂的氟代吡咯烷

Also Published As

Publication number Publication date
JPWO2002038541A1 (ja) 2004-03-18
WO2002038541A1 (fr) 2002-05-16
NO20031949L (no) 2003-07-08
CN1298703C (zh) 2007-02-07
CZ20031250A3 (cs) 2003-08-13
EE200300175A (et) 2003-06-16
HK1061688A1 (en) 2004-09-30
JP3987890B2 (ja) 2007-10-10
NO20054429L (no) 2003-07-08
EP1333025A1 (en) 2003-08-06
KR100620944B1 (ko) 2006-09-19
HUP0302248A2 (hu) 2003-10-28
EA006204B1 (ru) 2005-10-27
KR20060061410A (ko) 2006-06-07
BR0114851A (pt) 2003-09-16
PL361463A1 (en) 2004-10-04
AU1274502A (en) 2002-05-21
CA2428271C (en) 2005-12-27
KR100680079B1 (ko) 2007-02-09
EA008226B1 (ru) 2007-04-27
IL155776A0 (en) 2003-12-23
EA200300559A1 (ru) 2003-10-30
HRP20070116A2 (en) 2007-07-31
HRP20030366A2 (en) 2004-08-31
SK5632003A3 (en) 2003-12-02
AU2002212745B2 (en) 2007-01-04
BG107799A (bg) 2004-08-31
EP1746086A1 (en) 2007-01-24
WO2002038541A9 (fr) 2002-08-08
CA2428271A1 (en) 2002-05-16
KR100680081B1 (ko) 2007-02-09
EP1333025A4 (en) 2004-03-24
US20040072892A1 (en) 2004-04-15
NZ525705A (en) 2004-04-30
US20070112059A1 (en) 2007-05-17
TWI243162B (en) 2005-11-11
CN1474809A (zh) 2004-02-11
NO20031949D0 (no) 2003-04-29
KR20050096206A (ko) 2005-10-05
KR20030059232A (ko) 2003-07-07
EA200500852A1 (ru) 2006-02-24
IL182030A0 (en) 2007-07-24
US20070112205A1 (en) 2007-05-17

Similar Documents

Publication Publication Date Title
MXPA03004114A (es) Derivados de cianopirrolidina.
AU2002212745A1 (en) Cyanopyrrolidine derivatives
MXPA03002410A (es) 4-amino-quinazolinas.
ZA200206198B (en) New aza-indolyl derivatives.
ZA200000894B (en) 4-Phenyl-pyridine derivatives.
MXPA03005270A (es) Derivados de piperazina.
ZA200201055B (en) Amino-triazolopyridine derivatives.
MXPA03005445A (es) Barra colectora 12c para aislar los circuitos integrados seleccionados para una comunicacion rapida de barra colectora 12c.
ZA200205479B (en) Novel biarylcarboxamides.
ZA200207331B (en) Ethylenediamine derivatives.
MXPA03000939A (es) Derivados de imidazol.
ZA200109595B (en) 13-methyl-erythromycin derivatives.
HK1046411A1 (en) 5-Phenyl-pyrimidine derivatives.
EG23262A (en) Delta -pyrrolines.
HK1051863A1 (en) Indol-3-yl derivatives.
HK1056872A1 (en) Indoloquinazolinones.
MXPA03001591A (es) Derivados y analogos de 10-aril-11-h-benzo(b) fluorena para uso medicinal.
MXPA03001877A (es) 2-guanidin-4-arilquinazolinas.
MXPA03002668A (es) Guanidinas de sulfonilo.
MXPA03001991A (es) Novedosas arilalcano-sulfonamidas.
MXPA03005714A (es) Sulfamidotienopirimidinas.
HK1050889A1 (en) Substituted aminomehyl-phenyl-cyclohexane derivatives.
HK1052925A1 (en) Substituted 1-aminobutan-3-ol derivatives.
MXPA03002411A (es) 4-amino-quinazolinas.
ZA200205482B (en) Aminosulfonylbiphenyl derivatives.

Legal Events

Date Code Title Description
FG Grant or registration